Back to Authors

LeWitt, Peter A.

0000-0002-4976-4445

A5017122855 | I185443292

Mayo Clinic

Wayne State University

Citations 6

CSF α-Synuclein Seed Amplification Assays and Skin Immunofluorescence

Neurology | January 13, 2026 | Volume: 106 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000214648 | PMID 41529231

Design of a Phase 2 Study of Suvecaltamide in Moderate-to-severe Parkinson’s Disease Tremor (P9-3.009)

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000206381

ANCHOR-CD ( A bobotulinumtoxinA N eurotoxin: C linical and H ealth Economics O utcomes

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p07.191

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 | PMID 34519802

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting

Neurology | December 13, 2017 | Volume: 90 | Issue: 2 | Pages: 74-82

10.1212/wnl.0000000000004798 | PMID 29237794

3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis

Movement Disorders | July 19, 2013 | Volume: 28 | Issue: 12 | Pages: 1653-1660

10.1002/mds.25555 | PMID 23873789

ABSTRACT Parkinson's disease (PD) biomarkers are needed to enhance therapeutics research and to understand PD pathogenesis. Methods that simultaneously measure hundreds of small molecular‐weight compounds—metabolomic analysis–“fingerprint” disease‐specific alterations in individual compounds or metabolic pathways. Beyond a nontargeted search for PD biomarkers, we hypothesized that PD cerebrospinal fluid would show increased formation of the excitotoxin 3‐hydroxykynurenine and diminished concentration of the antioxidant glutathione. Cerebrospinal fluid was collected at <4 hours postmortem from 48 pathologically‐verified PD subjects and 57 comparably‐aged controls. Assays involved ultra‐high‐performance liquid and gas chromatography linked to mass spectrometry. We used univariate techniques to determine fold‐changes in concentrations of biochemicals; false‐discovery rates were calculated to exclude spurious findings. Data was modeled using a Support Vector Machine for analyzing compounds selected by Welch's t test. Classification accuracy was determined by cross‐validation. Of 243 structurally‐identified biochemicals,19 compounds differentiated PD from controls at a 20% false‐discovery level. In PD, mean 3‐hydroxykynurenine concentration was increased by one‐third, and mean oxidized glutathione was decreased by 40% (for each, P < .01). Four of the 19 compounds differentiating PD from controls were N‐acetylated amino acids, suggesting a generalized alteration in N‐acetylation activity. The Support Vector Machine classification model distinguished between groups at 83% sensitivity and 91% specificity for the learning data, and at 65% and 79% from cross‐validation. In this study, the first for metabolomic profiling of PD cerebrospinal fluid, we found several novel biomarkers and offer new directions for recognizing disease‐specific biochemical indicators. The findings support involvement of excitotoxicity and oxidative stress in the pathogenesis of PD. © 2013 International Parkinson and Movement Disorder Society